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Background: Viruses exploit a variety of cell surface receptors to infect their hosts.
Results: An integrin recognition motif in AAV9 was found to play a multifunctional role in systemic transport and cellular uptake.
Conclusion: Recombinant AAV vectors might exploit integrins during cellular uptake in different host tissues.
Significance: Host-receptor interactions influence the biodistribution of recombinant AAV vectors.
Adeno-associated viruses (AAVs) display a highly conserved
NGR motif on the capsid surface. Earlier studies have estab-
lished this tripeptide motif as being essential for integrin-medi-
ated uptake of recombinant AAV serotype 2 (AAV2) in cultured
cells. However, functional attributes of this putative integrin
recognition motif in other recombinant AAV serotypes display-
ing systemic transduction in vivo remain unknown. In this
study, we dissect the biology of an integrin domain capsid
mutant derived from the human isolate AAV9 in mice. The
AAV9/NGA mutant shows decreased systemic transduction in
mice. This defective phenotype was accompanied by rapid clear-
ance of mutant virions from the blood circulation and nonspe-
cific sequestration by the spleen. Transient vascular hyperper-
meability, induced by histamine coinjection, exacerbated
AAV9/NGA uptake by the spleen but not the liver. However,
such treatment did not affect AAV9 virions, suggesting a poten-
tial entry/post-entry defect for the mutant in different tissues.
Further characterization revealed modestly decreased cell sur-
face binding but a more pronounced defect in the cellular entry
of mutant virions. These findings were corroborated by the
observation that blocking multiple integrins adversely affected
recombinant AAV9 transduction in different cell types, albeit
with variable efficiencies. From a structural perspective, we
observed that the integrin recognition motif is located in close
proximity to the galactose binding footprint on AAV9 capsids
and postulate that this feature could influence cell surface
attachment, cellular uptake at the tissue level, and systemic
clearance by the reticuloendothelial system.
Adeno-associated viruses (AAVs)3 belong to the Dependovi-
rus genus of the Parvoviridae subfamily (1, 2). These small, non-
enveloped, single-strand DNA viruses are classified into six dis-
tinct clades, A through F, isolated from several different animal
sources (3). The subject of this study, AAV serotype 9/AAV
isolate Hu.14, belongs to clade F. Of the numerous recombinant
AAV strains currently being developed into gene transfer vec-
tors, AAV9 is one of few isolates that has displayed a propensity
to traverse the vasculature with high efficiency following
systemic administration. Consequently, widespread and robust
transduction of multiple tissues, including the heart, liver, skel-
etal muscle, lung, and, notably, the brain, by AAV9 vectors has
been reported (4). Efforts to understand the structural attri-
butes and molecular mechanisms that facilitate the systemic
transduction profile of recombinant AAV9 are ongoing. Key
findings to date include cryo-EM and x-ray crystallographic
determination of the three-dimensional structure of the AAV9
capsid (5), the discovery of galactosylated glycans as the pri-
mary cell surface attachment factor for AAV9 (6, 7), elucidation
of the residues that form the galactose-binding footprint (8),
and functional annotation of several other key residues on the
AAV9 capsid (9).
The first critical step in recombinant AAV transduction,
much like other non-enveloped viruses, involves recognition of
glycans for cell surface attachment (10). Subsequent to binding,
cellular uptake of different AAV serotypes appears to involve
specific coreceptors on the cell surface. For instance, the FGF
receptor is exploited by AAV2 (11), whereas the hepatocyte
growth factor receptor/C-Met appears to be utilized by both
AAV2 and AAV3 (12, 13). Further, platelet-derived growth fac-
tor and epidermal growth factor receptors have been impli-
cated in the cellular uptake of AAV5 and AAV6, respectively
(14, 15). In addition to these coreceptors that presumably con-
tribute to the differential transduction profiles of recombinant
AAV serotypes, earlier reports have implied an essential role for
integrins in the cellular uptake of AAV2 capsids (16, 17).
Importantly, the identification of a highly conserved integrin
binding motif (NGR) in the major capsid protein (VP3) subunit
of a vast majority of AAV serotypes might suggest a nonspecific
role for integrins in recombinant AAV transduction (18).
Previous studies by our laboratory demonstrated that glycan
binding avidity plays a critical role in determining the systemic
fate of different AAV serotypes following intravenous adminis-
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tration (19). In this report, we expand our mechanistic under-
standing of AAV systemic transport by interrogating the role of
integrins in viral uptake in vitro and systemic transport in vivo.
Specifically, we validate the functional role of the integrin bind-
ing NGR motif within the context of another recombinant AAV
serotype, i.e. AAV9, through both in vitro and in vivo experi-
ments. Further, we present data that confirm the essential role
played by different integrins in mediating AAV cell entry. Our
results clearly demonstrate that the inability to engage integrins
in vivo can adversely affect cellular entry of mutant AAV9
within different tissues. This defect is accompanied by rapid
clearance of mutant vectors from the systemic circulation
because of nonspecific uptake by the reticuloendothelial
system.
MATERIALS AND METHODS
Plasmids and Mutants—The R514A mutation resulting in the
disruption of the putative integrin recognition motif 512NGR514 to
non-functional 512NGA514 was introduced into the AAV9 Cap
gene in the plasmid pXR9 using the QuikChange site-directed
mutagenesis kit (Agilent Technologies, Santa Clara, CA). The
mutagenesis primer 5-GCTTCTTCTTGGGCTCTCAATGGA-
GCCAATAGCTTGATGAATCCTGG-3 (IDT, Coralville, IA)
was utilized to generate individual clones that were sequenced and
verified by the UNC Genome Analysis facility. Sequence analysis
and alignments were carried out using VectorNTI software
(Invitrogen).
Virus Production and Titers—Recombinant AAV9 and the
AAV9/NGA mutant packaging reporter transgenes were gen-
erated using an updated triple plasmid transfection and purifi-
cation method described earlier (20). The plasmids utilized
were the AAV9 helper pXR9 or pXR9/NGA, pXX6 – 80
expressing adenoviral helper genes, and pTR-CBA-Luc con-
taining the chicken -actin (CBA) promoter-driven firefly
luciferase transgene flanked by AAV inverted terminal repeats
derived from the AAV2 genome. Viral titers were obtained by
quantitative PCR using a Roche Lightcycler 480 (Roche
Applied Sciences). Quantitative PCR primers were designed to
specifically recognize the luciferase transgene (forward,
5-CTT CTT GGG CTC TCA ATG GAG CTA ATA GCT TGA
TGA ATC CTG-3; reverse, 5-CAG GAT TCA TCA AGC
TAT TAG CTC CAT TGA GAG CCC AAG AAG-3).
Cell Lines, Anti-integrin Antibodies, and Lentiviral shRNA
Constructs—CHO Lec2 cells were maintained in  modified
Eagle’s medium, whereas HEK293 and HeLa cells were cultured
in Dulbecco’s modified Eagle’s medium supplemented with
10% FBS, 100 units/ml of penicillin, 100 g/ml of streptomycin,
and 2.5 g/ml of amphotericin B (Sigma-Aldrich, St. Louis,
MO). Cells were maintained in 5% CO2 at 37 °C unless indi-
cated otherwise. Primary human umbilical vein endothelial
cells (HUVECs) were cultured in endothelial growth medium 2
with added supplements (Lonza, Allendale, NJ). Unless indi-
cated otherwise, different cell lines were desialylated prior to
AAV9 infection by treatment with recombinant sialidase
(neuraminidase, Sigma) as described earlier (7) to expose the
cell attachment receptor, i.e. terminal galactose.
For competitive inhibition studies, anti-integrin antibodies
directed against different  and  subunit combinations were
obtained from Abcam (catalog no. ab24694, mouse monoclonal
(P1F6) to integrin  V   5; catalog no. ab78289, mouse mono-
clonal (27.1 (VNR-1)) to integrin  V   3; catalog no.
ab30388, mouse monoclonal (JB1B) to integrin  1; catalog no.
ab16821, mouse monoclonal (272-17E6) to integrin  V; cata-
log no. ab75472, mouse monoclonal (P1D6) to integrin  5  
1; and catalog no. ab75872, rabbit monoclonal (EPR2417Y) to
integrin  3). This specific subset of antibodies was selected for
evaluation on the basis of prior studies implicating different
integrins in AAV2 infection (16 –18). Desialylated HEK293
cells, HeLa cells, or HUVECs with exposed surface galactose
were then pretreated with anti-integrin antibodies (20 g/ml)
for 60 min at 37 °C to facilitate receptor blockade prior to infec-
tion with AAV9 (1000 vg/cell). Transduction efficiency was
then determined by quantitation of luciferase transgene
expression in cell lysates with D-luciferin (Promega) as sub-
strate on a Victor2 luminometer (PerkinElmer Life Sciences).
For stable knockdown of integrins, HeLa cells were plated at
a density of 5  104 cells/well in a 24-well plate and allowed to
attach overnight. Cells were infected with shRNA-expressing
lentiviral vectors obtained from the University of North Caro-
lina lenti-shRNA core facility via spin infection in the presence
of 4 M Polybrene. On the basis of results from antibody block-
ing studies described earlier, only the integrin  3 subunit was
chosen as a target for knockdown (three clones targeted against
ITGB3, NM_000212.2, oligo ID no. TRCN0000003236-3238).
Detailed information pertaining to these constructs are avail-
able on the GenomeRNAi database (21–23). Lentiviral vectors
expressing shRNA against the GFP transgene were utilized as a
control. The virus was removed 24 h post-infection, and selec-
tion with 1 M puromycin was initiated 48 h post-infection.
Selection was continued for 48 h, and then cells were synchro-
nously infected with ssAAV9-CBA-fLuc at a multiplicity of
infection of 10,000 g/cell. Luciferase activity was assayed 24 h
post-infection as described above.
Cellular Binding, Uptake, and Transduction Assays—CHO
Lec2 cells were seeded in 24-well plates at a density of 1  105
cells/well 18 h prior to the experiment. The cells were first
prechilled at 4 °C for 30 min, and then AAV9 or AAV9/NGA
packaging the CBA-luc transgene was incubated on Lec2 cells
at 4 °C for 1 h at 1000 vg/cell, followed by three washes with
ice-cold 1 PBS to remove unbound virions. To quantitate the
number of cell surface-bound virions, 200 l of deionized H2O
was added to each well, and cells were subjected to three freeze-
thaw cycles prior to extraction of total genomic DNA using a
DNeasy kit (Qiagen, Germantown, MD). Viral genome titers
were then determined by qPCR as described earlier.
For cellular uptake studies following removal of unbound
virions, Lec2 cells in freshly added  modified Eagle’s
medium  10% FBS were moved to a 37 °C incubator to syn-
chronize virus internalization. After either 5 or 60 min of incu-
bation, cells were treated with 150 l/well of 0.05% trypsin at
37 °C for 5 min to release cell surface-associated virions. Tryp-
sin was then quenched by adding 150 l/well of DMEM with
10% FBS into each well, followed by three washes of the cell
pellets with ice-cold PBS. Total genomic DNA was then
extracted as described earlier and vg copy numbers were deter-
mined by qPCR.
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For transduction assays, Lec2 cells in freshly added  modi-
fied Eagle’s medium  10% FBS were infected with AAV9 or
AAV9/NGA (different multiplicities of infection) and main-
tained at 37 °C as outlined above. Cells were then lysed at 18 h
post-transduction to quantitate luciferase transgene expression
using a Victor2 luminometer (PerkinElmer Life Sciences).
Animal Studies—All animal experiments were carried out
using 6- to 8-week-old female BALB/c mice purchased from
Jackson ImmunoResearch Laboratories. Mice were maintained
and treated in accordance with NIH guidelines and as approved
by the University of North Carolina Institutional Animal Care
and Use Committee. BALB/c mice were injected intravenously
with AAV9 or AAV9/NGA vectors (1  1011 vg/animal)
through the tail vein. To image luciferase transgene expression
patterns in mice 3 weeks after vector administration, animals
were anesthetized with 2% isoflurane prior to intraperitoneal
injection of D-luciferin (120 mg/kg, Nanolight, Pinetop, AZ)
and imaged using an Xenogen IVIS Lumina system (PerkinEl-
mer Life Sciences/Caliper Life Sciences). To quantify luciferase
expression, mice subjected to live animal imaging were sacri-
ficed, and different tissues were harvested for analysis. Tissue
lysates were generated by adding 150 l of 2 passive lysis
buffer (Promega, Madison, WI) prior to mechanical lysis using
a Tissue Lyser II 352 system (Qiagen). Tissue lysates were then
pelleted to remove debris by centrifugation, and 50 l of the
supernatant from each lysate was subjected to luminometric
analysis using a Victor2 luminometer (PerkinElmer Life Sci-
ences). In addition, 2 l of supernatant was used for a Bradford
assay (Bio-Rad) to determine protein content in each sample.
For viral biodistribution analysis, different organs were har-
vested from BALB/c mice in the same treatment group that
were sacrificed 3 days or 3 weeks post-administration. Approx-
imately 50 mg of tissue from each systemic organ was pre-
treated with proteinase K prior to being homogenized using a
tissue lyser as described earlier. Total genomic DNA was then
extracted from tissue lysates using a DNeasy kit (Qiagen) and
viral genome copy numbers determined by qPCR of the lucif-
erase transgene using the same primers listed earlier. The num-
ber of cells in each sample was quantified using qPCR with
primers specific to the mouse LaminB housekeeping gene (for-
ward, 5-GGA CCC AAG GAC TAC CTC AAG GG-3;
reverse, 5-AGG GCA CCT CCA TCT CGG AAA C-3).
For pharmacokinetic analysis, BALB/c mice were injected
intravenously with 1  1011 vg copies of AAV9 or AAV9/NGA
vectors through the tail vein. 10-l aliquots of whole blood were
then collected by nicking the tail vein at the following time
points post injection: 5 min, 15 min, 30 min, 1 h, 3 h, 6 h, 24 h,
48 h, and 72 h. Total DNA was then extracted from each blood
sample using a Dneasy kit, and viral genome copy numbers
were measured by qPCR.
For histamine-induced vascular hyperpermeability studies, 5
mg of histamine (Sigma-Aldrich) was dissolved in 200 l of PBS
containing AAV9-CBA-Luc or AAV9/NGA-CBA-Luc, and
vector doses ranging from 1–5  1011 vg were injected into
mice via the tail vein. Control animals received AAV9 or
mutant virions in PBS without histamine. Mice were sacrificed
30 min post-administration and perfused transcardially with
PBS followed by 4% paraformaldehyde in PBS. The spleen was
harvested, fixed overnight with 4% paraformaldehyde at 4 °C,
and then transferred to PBS. Tissue sections of 50 m were
processed using a Leica vibrating blade microtome, and immu-
nostaining for AAV9 capsids was carried out as described ear-
lier (19). Briefly, a 10-fold dilution of hybridoma medium con-
taining monoclonal anti-AAV9 antibodies (ADK9) followed by
Alexa Fluor 647 goat-anti-mouse secondary antibody was uti-
lized to carry out these studies. Immunostained tissue sections
were mounted with ProLong Gold antifade reagent with DAPI
(Invitrogen) and imaged with a Zeiss 710 confocal microscope
with a 63 oil objective.
Structural Modeling—Coordinates for the AAV2 and AAV9
viral protein (VP) crystal structures were obtained from the
RCSB Protein Data Bank (PDB codes 1LP3 and 3UX1, respec-
tively) (5, 24). Three-dimensional models of the AAV2 and
AAV9 VP3 subunit trimers were created using the Oligomer
Generator utility in VIPERdb-Virus Particle ExploreR2 (25).
Structural models were then visualized using PyMOL, with
heparan sulfate binding residues on AAV2 (VP1 numbering
Arg484, Arg487, Lys532, Arg585, and Arg588) (26 –29) and the
galactose binding residues on AAV9 (VP1 numbering Asp271,
Asn272, Tyr446, Asn470, and Trp503) (8). The putative integrin
recognition motif is highlighted by residues 511NGR513 on
AAV2 and 512NGR514 (VP1 numbering) on AAV9.
Statistical Analysis—All data are expressed as mean  S.E.
Unless specified otherwise, a two-tailed unpaired Student’s t
test was used for all statistical analyses. p  0.05 was considered
significant (*, p  0.05; **, p  0.01; ***, p  0.005).
RESULTS AND DISCUSSION
Mutation of the AAV9 integrin recognition motif (NGR)
abrogates transduction in vivo. Intravenously administered
recombinant AAV9 virions likely interact first with the vascular
endothelium before uptake by other cell types in major sys-
temic organs such as the heart, lung, and liver (19, 30). To
address the impact of the NGA mutation in vivo, we studied the
transduction profile and pharmacokinetics of recombinant
AAV9 and AAV9/NGA vectors in mice. As shown in Fig. 1A,
live animal bioluminescent images obtained 3 weeks after vec-
tor administration display a significant decrease in luciferase
reporter transgene expression in the case of the AAV9/NGA
mutant. These data were further corroborated by quantitative
assessment of luciferase expression in tissue lysates obtained
from major systemic organs, including the brain, heart, liver,
lung, and spleen (Fig. 1B). Specifically, the AAV9/NGA mutant
displays a more than 100-fold reduction in transduction in the
murine heart and liver.
The AAV9/NGA mutant is cleared rapidly from the blood
circulation and sequestered by the spleen. To understand the
mechanism(s) resulting in decreased transduction efficiency of
AAV9/NGA particles, we first determined viral genome copy
numbers in different organs at two different time intervals. As
seen in Fig. 2, A and B, we observed a similar biodistribution
profile on days 3 or 21 after administration. Although vector
genome copy numbers were reduced 2- to 4-fold in major sys-
temic organs, these changes were not statistically significant
and could not fully explain the large defect in transduction of
the AAV9/NGA mutant. The lower vg copy numbers observed
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at the later time interval are expected because single-stranded
AAV genomes are known to be rapidly degraded following cap-
sid uncoating in different tissues (31–33). Interestingly, despite
the reduced transgene expression mediated by AAV9/NGA
vectors in the spleen, we observed a statistically significant ( a
log order) increase in vector genomes within this organ com-
pared with recombinant AAV9 vectors at both time intervals.
This observation suggests that AAV9/NGA particles are poten-
tially sequestered in large numbers by nonspecific mechanisms
such as phagocytic uptake by the reticuloendothelial system at
early time intervals. Nonspecific uptake of mutant AAV9/NGA
virions by endothelial cells lining different tissues could
potentially explain the modest decrease in vg copy numbers
within each tissue. Alternatively, it is possible that the mutant
virions are capable of successful trans-endothelial transport but
FIGURE 1. In vivo transduction profile of the AAV9NGA mutant in mice.
BALB/c mice (n  3) were injected intravenously with AAV9 (A) or AAV9/NGA
(B) vectors (1  1011 vg/mouse) through the tail vein. Luciferase transgene
expression patterns in mice were imaged using a Xenogen IVIS Lumina sys-
tem 3 weeks post-injection. Note that the rainbow scale indicates total flux
(photons/second/square centimeter/steradian) and is displayed at an order
of magnitude lower in B compared with A. To quantify luciferase expression
(C), mice subjected to live animal imaging were sacrificed at 3 weeks, and
different tissues were harvested for analysis. Tissue lysates from AAV9-treated
(gray columns) or AAV9NGA-treated (white columns) animals were subjected
to luminometric analysis using a Victor2 luminometer and normalized to the
mass of each tissue sample. Error bars represent mean  S.E. *, p  0.05; ***,
p  0.005. RLU, relative light unit(s).
FIGURE 2. Biodistribution and blood clearance of the AAV9NGA mutant in
mice. BALB/c mice (n  4) treated with AAV9 (gray bars) or AAV9NGA (white
columns) were sacrificed 3 days (A) or 3 weeks (B) after administration to
harvest different organs. Total genomic DNA was then extracted from lysates
obtained from homogenized tissue samples. Viral genome copy numbers
were normalized to the total number of copies of the mouse lamin gene in
each sample as determined by quantitative PCR. For pharmacokinetic analy-
sis (C), BALB/c mice (n  4) were injected intravenously with 1  1011 vg
copies of AAV9 (solid circles) or AAV9/NGA (triangles) vectors through the tail
vein. Viral genome copy numbers were determined by qPCR from 10-l ali-
quots of whole blood collected by nicking the tail vein at different time inter-
vals. Error bars represent mean  S.E. ***, p  0.005.
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suffer from a cellular entry defect after entering the tissue
interstitium.
The notion of reticuloendothelial system clearance is further
corroborated by the observation that AAV9/NGA virions are
rapidly cleared from the blood circulation following a single
intravenous bolus injection, as measured by quantitative PCR.
As shown in Fig. 2C, over a 72-h period, we observed striking
differences in the blood circulation profiles of AAV9 and
AAV9/NGA virions. Although tissue distribution profiles over-
lapped over the initial 6-h period, the AAV9/NGA virions were
more rapidly eliminated at later time intervals (24, 48, and 72 h).
These results suggest that mutant virions are likely defective in
binding/entry, resulting in rapid clearance from the blood cir-
culation by the spleen and endothelial system.
Increasing vascular permeability in tissues does not rescue
the AAV9/NGA mutant from splenic sequestration. We hy-
pothesized that if binding was the major defect, then we should
be able to reverse reticuloendothelial system clearance of
mutant AAV9/NGA virions, possibly by transiently perme-
abilizing the vascular wall and allowing entry into different tis-
sues. To test this hypothesis, we transiently permeabilized the
vasculature by coadministering histamine with AAV vectors
(34, 35). Confocal fluorescence microscopy of spleen and liver
tissues immunostained for AAV9 or mutant virions was then
carried out to assess the impact of vascular hyperpermeability
on vascular transport and systemic uptake. As shown in Fig. 3, A
and B, histamine coinjection does not appear to affect the accu-
mulation of AAV9 capsids in the spleen or the liver (Fig. 3, E and
F), suggesting that systemic tissue uptake of these virions is fully
functional and does not benefit from increased vascular perme-
ability. In contrast, the AAV9/NGA mutant shows markedly
increased splenic accumulation rather than reversal of this phe-
nomenon in histamine-treated animals (Fig. 3, C and D). Liver
uptake of the mutant virions does not appear to be influenced
(Fig. 3, G and H). These results corroborate the notion that
AAV9/NGA virions suffer from defective cellular entry after
entering the tissue interstitial space. Concomitant with this
defect, mutant virions are subject to nonspecific, phagocytic
uptake mechanisms, predominantly within the spleen. The lat-
ter appears to be exacerbated by the administration of hista-
mine because increased vascular permeability does not alleviate
a cellular entry defect.
The AAV9/NGA mutant is defective in cell surface binding
as well as uptake. To further examine mechanisms underlying
the defective systemic transport displayed by the AAV9/NGA
mutant, we carried out transduction, binding, uptake, and con-
focal microscopy studies in the permissive CHO Lec2 cell line,
which overexpresses terminal galactose residues, the primary
attachment receptor for AAV9 (7). As shown in Fig. 4A, the
AAV9/NGA mutant is transduction-deficient at different mul-
tiplicities of infection in Lec2 cells. Assessment of cell surface
binding revealed that the AAV9/NGA mutant was defective
when compared with parental AAV9 in engaging galactose res-
idues on the Lec2 cell surface (Fig. 4B). Specifically, a compar-
ison of the binding potentials (defined as the ratio of the maxi-
mum binding capacity and the relative binding affinity of
virions per cell) revealed a value of 4.54  10	2 for AAV9 and
2.38  10	2 for AAV9/NGA particles. These results suggest
that one possible cause for the defective phenotype displayed by
the AAV9/NGA mutant is decreased cell surface binding
potential.
To further examine whether an 
50% decrease in cell surface
binding potential was sufficient to explain the defective trans-
port phenotype of AAV9/NGA virions, we subjected different
virions to a quantitative PCR-based cellular uptake assay.
Briefly, this experiment involves the removal of cell surface-
bound virions using trypsin and quantitation of internalized
virions alone. As indicated by the recovery of trypsin-resistant
virions (Fig. 4C), 
10% of total AAV9 vector genome copies
appear to be internalized 5 min post-incubation, and this
amount increases to 
25% at 60 min. In contrast, 1% of tryp-
FIGURE 3. Histamine-induced vascular hyperpermeability affects viral
sequestration patterns. BALB/c mice (n  4) were treated with AAV9 or
AAV9/NGA mutant virions alone or coinjected with histamine to concurrently
induce vascular hyperpermeability. Spleen (A–D) and liver (E–H) tissue sec-
tions were immunostained with the ADK9 mouse monoclonal antibody
against AAV9 capsids followed by an Alexa Fluor 647 goat anti-mouse sec-
ondary antibody (red). Immunostained tissue sections were mounted with
ProLong Gold antifade reagent with63 oil objective. Representative micro-
graphs obtained from multiple tissue samples are shown.
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sin-resistant AAV9/NGA vector genome copies is recovered at
5 min, indicating a defect in uptake. This effect is exacerbated at
60 min, when no cumulative increase in uptake of the AAV9/
NGA mutant is observed. In contrast, although the previously
characterized galactose binding-deficient mutant AAV9/
W503R (19) displays 0.1% uptake at 5 min, uptake of these
virions is doubled at 60 min. Therefore, although AAV9/
W503R is a true galactose binding mutant, the AAV9/NGA
mutant appears to be marginally deficient in galactose binding
and significantly defective in cellular uptake.
Multiple integrins can mediate AAV9 transduction. To
examine whether integrins might act as coreceptors for AAV9
transduction, we utilized several anti-integrin antibodies that
are known to block integrin function. All cell types described
here were treated with sialidase as described earlier to expose
cell surface galactose receptors to facilitate efficient AAV9
binding. As shown in Fig. 5, A and B, integrins composed of the
 V (but not the  5 subunit), when combined with  1,  3, or
 5 subunits, appear to play a role in AAV9 transduction. Spe-
cifically, antibodies targeted against different integrins blocked
AAV9 transduction in desialylated HEK293 cells 2- to 5-fold
and in desialylated HeLa cells 2- to 10-fold. Inhibition of V3
integrin had the most profound effect on transgene expression,
whereas the effect of blockade of V5 or 51 integrins in
these cell lines was minimal. To define a potential role for integ-
rins in vascular uptake of AAV9, we also assessed the role of
integrins in AAV9-mediated transduction of cultured endothe-
lial cells (HUVECs). As seen in Fig. 5C, transgene expression in
desialylated HUVECs appears to be modestly reduced when
AAV9 entry is blocked by inhibitory antibodies against 51,
V1, or V3 but not V5 integrins. However, it should be
noted that these results are not statistically significant. Because
3 integrin subunits appeared to be involved in both HEK293
and HeLa cells, we further evaluated AAV9 transduction effi-
ciency in stable HeLa cell lines subjected to lenti-shRNA-me-
diated knockdown of the integrin 3 subunit. The latter target
was chosen for knockdown because the V3 integrin
appeared to be essential in all cell lines tested so far. As shown in
Fig. 5D, the transduction efficiency of AAV9 vectors was
decreased 2- to 5-fold in desialylated HeLa integrin 3 knock-
down cell lines. Taken together, these results suggest that mul-
tiple integrins can influence AAV9 transduction in different
cell types, presumably in a redundant fashion and with variable
efficiencies.
Structure-function correlates of AAV9-glycan and AAV9-
integrin interactions. The structure of the icosahedral AAV9
FIGURE 4. Transduction, binding, and uptake of the AAV9NGA mutant in
CHO Lec2 cells. A, transduction efficiency of AAV9-CBA-Luc (white columns)
and AAV9NGA-CBA-Luc (black columns) on CHO Lec2 cells that contain sur-
face-exposed galactose essential for AAV9 infection at increasing multiplici-
ties of infection were determined 24 h post infection (n  4). B, sialic acid-
deficient CHO Lec2 cells were prechilled and incubated with AAV9 or
AAV9NGA particles at different multiplicities of infection ranging from 100 –
500,000 at 4 °C to allow binding without cellular uptake. Quantitative analysis
of dose-dependent AAV9 (solid circles) or AAV9NGA (triangles) attachment to
cell surfaces was assessed using qPCR to quantify viral genome copy number
and binding curves generated using a single-site binding model (n  5). The
inset shows data of capsid binding at earlier time intervals. C, for cellular
uptake studies following removal of unbound virions, viral genomes were
extracted from Lec2 cells either 5 (gray columns) or 60 min (white columns)
after incubation, and copy numbers were determined by qPCR. The percent-
age of internalized virions is derived from the ratio of total number of inter-
nalized virions normalized to the number of bound AAV9, AAV9NGA, or the
binding deficient AAV9/W503R virions per cell (n  5). Error bars represent
mean  S.E. *, p  0.05; ***, p  0.005. RLU, relative light unit(s).
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capsid has recently been determined using x-ray crystallogra-
phy and cryo-EM (5). Although the AAV9 capsid displays a
conserved surface topology similar to that observed in other
AAV strains, our understanding of structure-function corre-
lates that are unique to AAV9 continue to evolve. For instance,
previous studies have established the galactose receptor bind-
ing footprint on the AAV9 capsid through a combination of
mutagenesis and structural modeling (8). The amino acid resi-
dues that have been directly implicated in galactose recognition
include Asn470, Asp271, Asn272, Tyr446, and Trp503, which form
a binding pocket at the base of the protrusions around the ico-
sahedral three-fold axes of symmetry. In addition, several other
amino acid residues that indirectly affect galactose binding
have been mapped through random as well as alanine scanning
mutagenesis (9, 36). Mutagenesis of residues that affect glycan
recognition, thereby resulting in decreased or increased bind-
ing affinity, can have a profound impact on the transduction
efficiency, pharmacokinetics, and biodistribution of recombi-
nant AAV9 (9, 19, 36). We recently utilized this information to
successfully graft a functional galactose binding footprint onto
other AAV capsid templates (20). In addition, several other sin-
gle amino acid residues have recently been identified as being
essential for post-attachment processing and transduction of
multiple tissues by recombinant AAV9, although the underly-
ing molecular mechanisms have yet to be determined (9).
In this study, we assign the structure-function correlates of
one such subset of amino acid residues, i.e. an apparently pleio-
tropic role of the integrin-binding NGR motif in binding, cellu-
lar uptake and systemic clearance of recombinant AAV9 vec-
tors. A key explanation for this multifunctional attribute hinges
on the structural location of the NGR motif adjacent to the
galactose binding pocket on the AAV9 capsid (Fig. 6B). Previ-
ously, we mapped the location of the NGR motif on the AAV2
capsid to a site distinct from the heparan sulfate binding region
(Fig. 6A) at the icosahedral three-fold symmetry axis (18). In
FIGURE 5. Competitive inhibition and knockdown of integrin subunits affect AAV9 transduction. HEK293 cells (A), HeLa cells (B), and HUVECs (C) were
desialylated to expose the galactose receptor and pretreated with anti-integrin monoclonal antibodies directed against different  and  subunits followed by
infection with AAV9 vectors packaging a CBA promoter-driven firefly luciferase transgene (1000 vg/cell). Transduction efficiency was then determined by
luciferase bioluminescence assays performed 24 h post-infection (n  4). D, stable knockdown of the integrin 3 subunit was achieved with three different
anti-integrin 3 shRNAs (3236, 3237, and 3238) packaged within lentiviral vectors. Lentiviral vectors expressing an shRNA targeted against eGFP were utilized
as control. Clonally expanded HeLa integrin 3 knockdown or eGFP control cell lines were infected with AAV9-CBA-Luc (1000 vg/cell), and luciferase assays
were carried out 24 h post-infection (n  4). Error bars represent mean  S.E. **, p  0.01; ***, p  0.005; n.s., not significant. RLU, relative light unit(s).
FIGURE 6. Comparison of glycan and integrin recognition motifs on AAV2
and AAV9 capsid surfaces. Exterior capsid surface representation of VP3
subunit trimers for AAV2 (A) and AAV9 (B) generated using the Oligomer
Generator utility in VIPERdb-Virus Particle ExploreR2 and PyMOL. Different
VP3 monomers are colored in pale green, light blue, and light pink. The surface
location of heparan sulfate binding residues on AAV2 (VP1 numbering Arg484,
Arg487, Lys532, Arg585, and Arg588) and the galactose binding residues on
AAV9 (VP1 numbering Asp271, Asn272, Tyr446, Asn470, and Trp503) are high-
lighted in purple and orange, respectively. The integrin recognition motifs,
511NGR513 on AAV2 and 512NGR514 (VP1 numbering) on AAV9 are highlighted
in red. C, close-up views of superposed structures of AAV2 and AAV9 trimers
with one group of individual residues labeled in each. The overlapping NGR
motif is structurally conserved and located in closer proximity to the AAV9
galactose footprint than the AAV2 heparan sulfate binding footprint.
Integrin Receptors and AAV9
1502 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290 • NUMBER 3 • JANUARY 16, 2015
contrast to AAV2, where mutation of the NGR motif does not
affect heparin binding, it is conceivable that a similar alteration
of the NGR motif on AAV9 might indirectly affect glycan bind-
ing because of its close proximity to the galactose binding
pocket. These observations are corroborated by a closer exam-
ination of the different heparan sulfate and galactose binding
residues on the capsid surface as well as the NGR residues,
which appear to be structurally conserved in AAV2 as well as
AAV9 and, most likely, several other AAV serotypes (Fig. 6C).
Importantly, we establish, by subsequent analysis, that the NGR
motif is more critical for post-attachment processing mediated
by integrin receptors and, consequently, cellular entry within
different tissues, leading to successful transduction. When
these potential receptor interactions are compromised, our
results suggest that rapid clearance of recombinant AAV vec-
tors by nonspecific uptake mechanisms, such as by the spleen or
endothelial lining, is likely. In addition, although our studies
implicate integrins in the vascular uptake of AAV9, it is impor-
tant to note that these observations are likely distinct from
other possible coreceptors and/or mechanisms by which
recombinant AAV9 vectors might cross the vascular barrier.
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